RedHill Biopharma Ltd (RDHL)

[BioSpecialist]

Im back in on this brutally undervalued and almost unknown gem . There is a lot of News coming within next 6-7 months to drive this Low Float stock to new All Time Highs .Share Offering creates a fantastic buying opportunity today .GL


New Presentation
http://files.shareholder.com/downloads/AMDA-1C0OBF/3449232654x0x921626/E74E4AE5-D2D2-4BE5-AC65-E5500A956C12/RedHill_Biopharma_Corporate_Presentation_151216_.pdf


Upcoming Milestones Q4 2016:

Commercial asset: •Potential acquisition of certain commercial rights to GI asset currently on the market in the U.S.

1H 2017 :

RIZAPORT®(RHB-103):
•Re-submission of U.S. NDA


RHB-104:
•Second DSMB meeting for the MAP US Phase III study for Crohn’s disease, including safety and interim efficacy analysis, with evaluation of option of early stop for success for overwhelming efficacy -Q2/2017


BEKINDA®(RHB-102):
•Top-line Phase III results (gastroenteritis) -mid-2017
•Top-line Phase II results (IBS-D) -mid-2017


RHB-105 (H. pylori):
First Phase III study successfully met its primary endpoint with high statistical significance (p<0.001), confirmatory Phase III planned to be initiated H1/2017